Literature DB >> 9796064

Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts.

I Davidkin1, M Valle.   

Abstract

In Finland, a two-dose vaccination programme against measles, mumps and rubella (MMR) was begun in 1982. The programme with high coverage (97-98%) has eliminated these three diseases from Finland. The aim of the present study was to follow up the kinetics of measles virus antibodies in MMR vaccinated cohorts. We have followed the kinetics of measles virus antibody levels induced by vaccination in the same individuals immunized with their first MMR vaccine in 1982. After 12 years 80% of the original children remained available for sampling. Antibodies to measles virus were measured by haemagglutination inhibition (HI) and plaque reduction neutralization (NT) techniques. The primary dose induced 99.4% seroconversion for measles with a geometric mean HI antibody titre (GMT) of 1/269 (+/- 219), equivalent to 4304 mIU (milli-International Units) ml-1 in group A. The 12-year follow-up specimens showed a measles seropositivity rate of 100% as assayed with the HI and NT tests with a mean HI antibody titre of 1/39 (+/- 54), equivalent to 624 mIU ml-1. The vaccination-induced measles virus antibodies decline in the absence of natural booster infections. It is important to follow how long the protection achieved by the present vaccine programme will last after elimination of indigenous measles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796064     DOI: 10.1016/s0264-410x(98)00081-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Immunity to measles in the Croatian population.

Authors:  Berislav Borcić; Renata Mazuran; Bernard Kaić
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

3.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

4.  Assessment of the epidemiology and burden of measles in Southern Mozambique.

Authors:  Inácio Mandomando; Denise Naniche; Marcela F Pasetti; Lilian Cuberos; Sergi Sanz; Xavier Vallès; Betuel Sigauque; Eusébio Macete; Delino Nhalungo; Karen L Kotloff; Myron M Levine; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

5.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

7.  Fully vaccinated children are rare: immunization coverage and seroprevalence in Austrian school children.

Authors:  Markus Ringler; Georg Göbel; Johannes Möst; Kurt Weithaler
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

8.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

9.  Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.

Authors:  Amy Parker Fiebelkorn; Laura A Coleman; Edward A Belongia; Sandra K Freeman; Daphne York; Daoling Bi; Ashwin Kulkarni; Susette Audet; Sara Mercader; Marcia McGrew; Carole J Hickman; William J Bellini; Rupak Shivakoti; Diane E Griffin; Judith Beeler
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

10.  Asthma status and waning of measles antibody concentrations after measles immunization.

Authors:  Kwang Ha Yoo; Robert M Jacobson; Gregory A Poland; Amy Weaver; Linda Lee; Titus Chang; Young J Juhn
Journal:  Pediatr Infect Dis J       Date:  2014-10       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.